Appelbaum Fr

2.1k total citations
61 papers, 1.7k citations indexed

About

Appelbaum Fr is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Appelbaum Fr has authored 61 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 12 papers in Genetics and 11 papers in Oncology. Recurrent topics in Appelbaum Fr's work include Hematopoietic Stem Cell Transplantation (30 papers), Acute Myeloid Leukemia Research (11 papers) and Acute Lymphoblastic Leukemia research (9 papers). Appelbaum Fr is often cited by papers focused on Hematopoietic Stem Cell Transplantation (30 papers), Acute Myeloid Leukemia Research (11 papers) and Acute Lymphoblastic Leukemia research (9 papers). Appelbaum Fr collaborates with scholars based in United States and South Africa. Appelbaum Fr's co-authors include CD Buckner, Rainer Storb, JE Sanders, Clift Ra, K Doney, Thomas Ed, Jack W. Singer, Deeg Hj, Petersen Fb and A Fefer and has published in prestigious journals such as Cancer Research, Experimental Hematology and PubMed.

In The Last Decade

Appelbaum Fr

61 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Appelbaum Fr United States 26 1.3k 515 345 295 210 61 1.7k
Petersen Fb United States 19 1.4k 1.0× 502 1.0× 289 0.8× 404 1.4× 187 0.9× 28 1.8k
Irena Sniecinski United States 22 1.1k 0.8× 510 1.0× 212 0.6× 375 1.3× 281 1.3× 49 1.8k
P. B. Mcglave United States 19 1.3k 1.0× 394 0.8× 329 1.0× 472 1.6× 357 1.7× 24 1.7k
BW Goodell United States 8 1.2k 0.9× 439 0.9× 328 1.0× 321 1.1× 270 1.3× 10 1.5k
R A Clift United States 14 1.2k 0.9× 596 1.2× 292 0.8× 204 0.7× 183 0.9× 18 1.7k
J Cahn France 22 1.2k 0.9× 392 0.8× 364 1.1× 330 1.1× 216 1.0× 70 1.6k
W. G. Ho United States 22 1.3k 1.0× 413 0.8× 193 0.6× 559 1.9× 271 1.3× 38 1.7k
J Gmür Switzerland 20 1.3k 1.0× 366 0.7× 180 0.5× 218 0.7× 243 1.2× 51 1.7k
MR O’Donnell United States 16 982 0.8× 358 0.7× 405 1.2× 150 0.5× 208 1.0× 25 1.4k
Norbert Frickhofen Germany 18 1.0k 0.8× 412 0.8× 175 0.5× 414 1.4× 320 1.5× 34 1.9k

Countries citing papers authored by Appelbaum Fr

Since Specialization
Citations

This map shows the geographic impact of Appelbaum Fr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Appelbaum Fr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Appelbaum Fr more than expected).

Fields of papers citing papers by Appelbaum Fr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Appelbaum Fr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Appelbaum Fr. The network helps show where Appelbaum Fr may publish in the future.

Co-authorship network of co-authors of Appelbaum Fr

This figure shows the co-authorship network connecting the top 25 collaborators of Appelbaum Fr. A scholar is included among the top collaborators of Appelbaum Fr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Appelbaum Fr. Appelbaum Fr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fr, Appelbaum. (1999). Antibody-targeted therapy for myeloid leukemia.. PubMed. 36(4 Suppl 6). 2–8. 46 indexed citations
2.
Fr, Appelbaum. (1999). Introduction: emerging therapies for hematologic malignancies: antibodies, antisense, and cytokine approaches. PubMed. 36(4 Suppl 6). 1–1. 3 indexed citations
3.
Fr, Appelbaum. (1997). Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL).. PubMed. 11 Suppl 4. S15–7. 41 indexed citations
4.
Demirer, Taner, Ted Gooley, CD Buckner, et al.. (1995). Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation.. PubMed. 15(6). 907–13. 51 indexed citations
5.
Demirer, Taner, CD Buckner, Appelbaum Fr, et al.. (1995). Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.. PubMed. 15(6). 915–22. 34 indexed citations
6.
Ra, Clift, Deeg Hj, Rainer Storb, et al.. (1994). Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia.. PubMed. 14(6). 885–93. 35 indexed citations
7.
Doney, K, CD Buckner, Lloyd D. Fisher, et al.. (1993). Autologous bone marrow transplantation for acute lymphoblastic leukemia.. PubMed. 12(4). 315–21. 29 indexed citations
8.
Buckner, CD, Clift Ra, Appelbaum Fr, et al.. (1991). Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia.. PubMed. 7 Suppl 2. 6–8. 25 indexed citations
9.
Buckner, CD, Clift Ra, Appelbaum Fr, et al.. (1991). Effects of treatment regimens on post marrow transplant relapse.. PubMed. 28(3 Suppl 4). 32–4. 9 indexed citations
10.
Graham, TC, et al.. (1990). Transfusion of autologous cytotoxic cells leads to failure of unrelated, DLA-nonidentical marrow grafts.. PubMed. 18(10). 1126–31. 2 indexed citations
11.
Fr, Appelbaum, T. Graham, BM Sandmaier, F Schuening, & R Storb. (1988). Sensitivity of newly transplanted marrow to further irradiation.. PubMed. 45(4). 813–4. 3 indexed citations
12.
Fb, Petersen, Appelbaum Fr, CD Buckner, et al.. (1988). Simultaneous infusion of high-dose cytosine arabinoside with cyclophosphamide followed by total body irradiation and marrow infusion for the treatment of patients with advanced hematological malignancy.. PubMed. 3(6). 619–24. 14 indexed citations
13.
Fr, Appelbaum, et al.. (1987). Use of iodine-131-labeled anti-immune response-associated monoclonal antibody as preparative regimen prior to bone marrow transplantation: initial dosimetry.. PubMed. 67–71. 7 indexed citations
14.
Storb, Rainer, Jessica Whitehead, Vernon T. Farewell, et al.. (1987). Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.. PubMed. 19(1 Pt 3). 2608–13. 25 indexed citations
15.
Fb, Petersen, CD Buckner, D. B. Amos, et al.. (1985). Marrow harvesting for autologous marrow transplantation.. PubMed. 13(9). 879–84. 23 indexed citations
16.
Fr, Appelbaum, et al.. (1982). Fatal hepatotoxicity associated with AMSA therapy.. PubMed. 66(10). 1863–65. 10 indexed citations
17.
Fr, Appelbaum, et al.. (1979). Accelerated hemopoietic recovery following the infusion of cryopreserved autologous bone marrow in humans.. PubMed. 7 Suppl 5. 297–301. 10 indexed citations
18.
Fr, Appelbaum. (1979). Hemopoietic reconstitution following autologous bone marrow and peripheral blood mononuclear cell infusions.. PubMed. 7 Suppl 5. 7–11. 23 indexed citations
19.
As, Levine, Appelbaum Fr, Graw Rg, et al.. (1978). Sequential combination chemotherapy (containing high-dose cyclophosphamide) for metastic osteogenic sarcoma.. PubMed. 62(2). 247–50. 4 indexed citations
20.
Fr, Appelbaum, et al.. (1977). Treatment of refractory acute leukemia with high-dose chemotherapy.. PubMed. 61(7). 1397–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026